Observational Study in Patients With HIV Infection Type 1 After Switching to a Viramune®-Containing Therapy Regimen

Boehringer Ingelheim

Status: Completed

Conditions: HIV Infections

Treatments: Drug: Viramune

Study type: Observational

Funder types: Industry

Identifiers

NCT02191332

1100.1305

Details and patient eligibility

About

Observational study to collect data on maintaining anti-retroviral activity (quantitative HIV RNA determination) and immunological activity (CD4 cells) despite switching from protease inhibitor to nonnucleoside reverse transcriptase inhibitor (NNRTI) (Viramune®).

Enrollment: 147 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult male or female patients with HIV type 1 infection

Exclusion criteria

• Counter-indications according to summary of product characteristics (SPC) for Viramune tablets
• No persons under 18
• Pregnancy and breast-feeding
• Use of oral contraceptives
• Use of drugs affecting CYP450 3A metabolism

Trial design

147 participants in 1 patient group

Viramune

Treatment:

Drug: Viramune